Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game

被引:5
|
作者
Groisberg, Roman [1 ]
Subbiah, Vivek [2 ,3 ,4 ]
机构
[1] Rutgers Canc Inst New Jersey, Dept Melanoma Sarcoma Med Oncol & Phase 1, New Brunswick, NJ USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, 1515 Holcombe Blvd, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Network, Houston, TX 77030 USA
关键词
D O I
10.1158/1078-0432.CCR-21-0254
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The single-agent activity of MEK inhibitors in MAPK or CDK4/6 inhibitors in cyclin pathway aberrant tumors has been limited. The combination of trametinib and palbociclib demonstrates safety, tolerability, and clinical activity in a histology-independent manner, representing a therapeutic approach for patients harboring co-occurring aberrations.
引用
收藏
页码:2672 / 2674
页数:3
相关论文
共 50 条